Postnatal Oxytocin Treatment and Cognitive Function in Fragile X
脆性 X 肌瘤的产后催产素治疗和认知功能
基本信息
- 批准号:10383734
- 负责人:
- 金额:$ 47.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-05 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:ASD patientAcuteAddressAdultAffectAgonistAnimal ModelBehaviorBehavioralBehavioral MechanismsBrainBrain regionBrain-Derived Neurotrophic FactorCenters for Disease Control and Prevention (U.S.)ChildChildhoodCognitiveDTR geneDevelopmentDiseaseElectrophysiology (science)ElementsEpidermal Growth Factor ReceptorEpisodic memoryExcitatory SynapseExhibitsFMR1FemaleFragile X SyndromeFutureGoalsHippocampus (Brain)Hypothalamic structureImpaired cognitionInheritedInhibitory SynapseIntellectual functioning disabilityKnockout MiceKnowledgeLearningLifeLocationLong-Term PotentiationMeasuresMediatingMemoryMemory impairmentModelingMorphologyNeurobiologyNeurodevelopmental DisorderNeuronsNeuropeptidesNeurotrophic Tyrosine Kinase Receptor Type 2OXT geneOdorsOxytocinOxytocin ReceptorPeptidesPhenotypePhysiologicalProcessPropertyProteinsReceptor Protein-Tyrosine KinasesReceptor SignalingRegimenRegulationRodent ModelRoleRouteSignal TransductionSocial BehaviorSocial InteractionStructureSynapsesSynaptic ReceptorsSynaptic plasticitySystemTechniquesTestingTherapeuticThinkingTrophic Factor ReceptorVertebral columnWild Type MouseWorkautism spectrum disordercellular targetingcognitive functioncomorbiditycritical developmental periodcritical perioddesigndevelopmental diseaseearly phase clinical trialimprovedindividuals with autism spectrum disorderinterestmalememory encodingmouse modelmutantnovelpersonal narrativespostnatalpostnatal periodresponserestorationsexsocialsynaptic functiontherapeutic candidatetherapeutically effective
项目摘要
Autism Spectrum Disorder (ASD) is a prevalent and heterogeneous neurodevelopmental disorder with high co-
morbidity for intellectual disability. This includes difficulties forming episodic, personal narrative, memories that
are critical for orderly thinking and organizing future behaviors. Episodic memory deficits are thus thought to be
major contributors to cognitive difficulties associated with autism. Many brain changes underlying abnormalities
in ASD appear in childhood suggesting the possibility for effective therapeutic strategies targeting brain
maturation. One candidate therapeutic is the hypothalamic peptide Oxytocin (OXT). Postnatal OXT treatment
improves social behavior in animal models of ASDs and recent work indicates that treatment in childhood
improves social interactions in autistic individuals. OXT acutely facilitates forms of synaptic plasticity, but there
has been little experimental consideration of possible enduring effects of postnatal OXT treatment on learning
and no analyses of effects on episodic memory. We examined this possibility using intranasal OXT (iOXT)
treatment in the Fmr1 KO mouse model of Fragile X Syndrome, and novel paradigms for analyses of `What,
When and Where' encoding. Our preliminary results show that in Fmr1 KOs iOXT treatments during the
second postnatal week (P7-13) fully rescue hippocampal field CA1 long-term potentiation, object location
memory, object identity (What) learning, and social recognition as assessed in adulthood (i.e., >40d after the
last treatment). These findings raise the exciting possibility that a limited period of early life OXT treatment can
effect a life-long rescue of a critical element of cognitive function in ASD. They also raise questions as to the
breadth of effects iOXT has on behavior and the mechanisms involved; these questions will be addressed in
the proposed studies. Aim 1 studies will test if postnatal iOXT treatment of male and female Fmr1 KO mice
rescues encoding for the three major components of episodic memory, social recognition and stereotypic
behavior as assessed in adulthood, and if effects depend on native OXT efflux. We will also determine if there
is a critical period for enduring iOXT effects on behavior. Aim 2 will use electrophysiological recordings of
evoked responses and network activity, analyses of synaptic proteins and signaling, and measures of neuronal
arbors to test if postnatal iOXT treatment normalizes neurobiological processes in the distinct hippocampal
subdivisions related to episodic memory encoding. Finally, Aim 3 will test the hypothesis that early life iOXT
leads to activation of synaptic trophic factor receptors (EGFR, TrkB) in hippocampus, thereby suggesting a
direct route for OXT effects on maturational changes in the structure. Overall, the proposed studies will greatly
expand our current knowledge of OXT actions in the young brain, including potentially critical roles in
regulating hippocampal development and synaptic function. Moreover, the results will lay the groundwork for
designing novel, early life regimens to optimize hippocampal maturation and function, and to rescue the
encoding of episodic memories in ASD and related developmental disorders.
自闭症谱系障碍(ASD)是一种普遍存在的异质性神经发育障碍,
智力残疾的发病率。这包括难以形成情节,个人叙述,记忆,
对有序思考和组织未来行为至关重要。因此,情节记忆缺陷被认为是
与自闭症相关的认知困难的主要贡献者。许多大脑变化潜在的异常
在ASD中出现在儿童期,提示针对脑的有效治疗策略的可能性
成熟一种候选治疗剂是下丘脑肽催产素(OXT)。产后OXT治疗
在ASD动物模型中改善了社会行为,最近的研究表明,
改善自闭症患者的社会互动。OXT急性促进突触可塑性的形式,但有
关于出生后OXT治疗对学习可能产生的持久影响,
也没有分析对情景记忆的影响。我们使用鼻内OXT(iOXT)检查了这种可能性
在脆性X综合征的Fmr 1 KO小鼠模型中的治疗,以及用于分析“什么,
“何时何地”编码。我们的初步结果表明,在Fmr 1科斯iOXT治疗期间,
出生后第2周(P7-13)完全恢复海马CA 1区长时程增强,目标定位
记忆、物体身份(什么)学习和成年后评估的社会识别(即,> 40天后,
最后一次治疗)。这些发现提出了一种令人兴奋的可能性,即有限的早期OXT治疗可以
影响ASD认知功能关键要素的终身拯救。他们还提出了一些问题,
iOXT对行为和相关机制的影响范围;这些问题将在
建议的研究。目标1研究将测试雄性和雌性Fmr 1 KO小鼠的出生后iOXT治疗是否
拯救了情景记忆、社会认知和刻板印象三个主要组成部分的编码
行为在成年期评估,如果影响取决于天然OXT流出。我们还将确定是否有
是持续iOXT对行为影响的关键时期。目标2将使用电生理记录,
诱发反应和网络活动,突触蛋白和信号传导的分析,以及神经元
测试出生后iOXT治疗是否使不同海马中的神经生物学过程正常化的指标
与情景记忆编码相关的细分。最后,目标3将检验早期生命iOXT
导致海马中突触营养因子受体(EGFR,TrkB)的激活,从而表明
OXT对结构成熟变化的影响的直接途径。总体而言,拟议的研究将大大
扩大我们目前对OXT在年轻大脑中作用的了解,包括在以下方面的潜在关键作用:
调节海马发育和突触功能。此外,研究结果将为以下方面奠定基础:
设计新的早期生命方案,以优化海马的成熟和功能,并挽救海马的生命。
ASD和相关发育障碍中情景记忆的编码。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christine M Gall其他文献
Christine M Gall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christine M Gall', 18)}}的其他基金
Postnatal Oxytocin Treatment and Cognitive Function in Fragile X
脆性 X 肌瘤的产后催产素治疗和认知功能
- 批准号:
10611408 - 财政年份:2021
- 资助金额:
$ 47.6万 - 项目类别:
Postnatal Oxytocin Treatment and Cognitive Function in FragileX
FragileX 的产后催产素治疗和认知功能
- 批准号:
10842114 - 财政年份:2021
- 资助金额:
$ 47.6万 - 项目类别:
ICAL: Impact of Cannabinoids Across Lifespan: Pilot Project Core
ICAL:大麻素对整个生命周期的影响:试点项目核心
- 批准号:
10188477 - 财政年份:2018
- 资助金额:
$ 47.6万 - 项目类别:
ICAL: Impact of Cannabinoids Across Lifespan: Cellular Project
ICAL:大麻素对整个生命周期的影响:细胞项目
- 批准号:
10188479 - 财政年份:2018
- 资助金额:
$ 47.6万 - 项目类别:
Loss and rescue of endocannabinoid-dependent LTP and memory in Fragile-X model mice
Fragile-X 模型小鼠内源性大麻素依赖性 LTP 和记忆的丧失与挽救
- 批准号:
9332463 - 财政年份:2016
- 资助金额:
$ 47.6万 - 项目类别:
Loss and rescue of endocannabinoid-dependent LTP and memory in Fragile-X model mice
Fragile-X 模型小鼠内源性大麻素依赖性 LTP 和记忆的丧失与挽救
- 批准号:
9752269 - 财政年份:2016
- 资助金额:
$ 47.6万 - 项目类别:
Loss and rescue of endocannabinoid-dependent LTP and memory in Fragile-X model mice
Fragile-X 模型小鼠内源性大麻素依赖性 LTP 和记忆的丧失与挽救
- 批准号:
9502329 - 财政年份:2016
- 资助金额:
$ 47.6万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 47.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 47.6万 - 项目类别:
Operating Grants














{{item.name}}会员




